Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681299 · ClinicalTrials.gov registry record · Phase 4
Effects of GH and Lirglutide on AgRP
A Phase 4 study of Healthy and Growth Hormone Deficiency, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05681299: Recruiting Phase 4 study of Healthy and Growth Hormone Deficiency, sponsored by Columbia University.
NCT05681299 is a Phase 4 study of Healthy and Growth Hormone Deficiency that is actively recruiting participants, run by Columbia University. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05681299, a Phase 4 study of Healthy and Growth Hormone Deficiency, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of each arm will include blood sampling and assessments of insulin resistance, energy expenditure and body composition.
Primary Outcome
Difference in percent change in morning fasting level of AgRP (agouti-related peptide) in plasma in GH vs. placebo arms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG growth hormone and lirglutide
- DRUG growth hormone
- DRUG liraglutide
Study Locations (1)
New York
- Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 4 |
What NCT05681299 shows while recruiting
NCT05681299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05681299 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05681299 about?
NCT05681299 is a clinical study titled "Effects of GH and Lirglutide on AgRP". This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglu...
What is the current status of trial NCT05681299?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2023-05-01. Estimated completion is 2028-04-30.
What conditions does trial NCT05681299 study?
This clinical trial studies the following conditions: Healthy, Growth Hormone Deficiency.
What interventions are being tested in trial NCT05681299?
The interventions under investigation include: Placebo (DRUG), growth hormone and lirglutide (DRUG), growth hormone (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT05681299?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05681299 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05681299's enrollment target sits among peer trials
40 540th of 1090 higher than 513 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
-
VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI